CN108175853A - A kind of tumor cell vaccine and preparation method thereof - Google Patents
A kind of tumor cell vaccine and preparation method thereof Download PDFInfo
- Publication number
- CN108175853A CN108175853A CN201810067095.7A CN201810067095A CN108175853A CN 108175853 A CN108175853 A CN 108175853A CN 201810067095 A CN201810067095 A CN 201810067095A CN 108175853 A CN108175853 A CN 108175853A
- Authority
- CN
- China
- Prior art keywords
- cell
- tumor
- vaccine
- molecule
- tumour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
Abstract
The present invention relates to biological therapy fields more particularly to a kind of tumor cell vaccine and preparation method thereof.It can recognize that molecule modifies tumour cell in vitro by using antigen presenting cell, so the tumor cell vaccine after modification can be identified, and then swallowed by antigen presenting cell in vivo.Performance or submission are in cell surface after tumour cell content after endocytosis is processed (including tumor associated antigen molecule and neoantigen peptide) by antigen presenting cell, then corresponding immune effector cell is activated, start the W-response of immune system, achieve the purpose that limit tumor development and treat tumour.Tumor vaccine disclosed in the present invention is prepared simply, at low cost, and short preparation period, is that provides the art a kind of new effective tumor vaccines.
Description
Technical field
The present invention relates to biological therapy fields more particularly to a kind of tumor cell vaccine and preparation method thereof.
Background technology
The technology of immune cell therapy cancer can be divided into passive immunity and active immunity.Passive immunity uses external sharp
After input in vivo, it is thin directly to attack tumour for immune effector cell living, mainly CD8-T cells and its cell of derivative type
Born of the same parents.The major technique of this respect has CAR-T (Chimeric antigen receptor-T cell), CTL (Cytotoxic T lymphocytes), TCR-T (T
Cell receptor (TCR) mosaic type T cell), the technologies such as TIL (tumor infiltrating lymphocyte).The table of these cells clinically
Now happiness sorrow mixes half.In addition to CAR-T is effective to some blood cancers, therefore FDA ratifies two CAR-T launch, it is other all
Still in research or clinical experimental stage.The effect of one the fact that can not be ignored is, these cells are to solid tumor is all undesirable.
This limitation is appeared to be for cell therapy, because the antibody drug for identical target molecule can but effectively act on entity
Knurl.It can be seen that humoral immunity is one side indispensable (at least for solid tumor) in immunotherapy of tumors.
Now, active immunity treatment is generally referred to as with tumor cell vaccine and Immature dendritic shape cell vaccine immune cancer
Patient.Once, the extract of pathogen thalline and thalline was spare does vaccine immunity tumour patient, but this para-immunity means is
It is not re-used as the immunotherapeutic of cancer, therefore has been moved out of this classification.The patient's that earliest tumor vaccine uses is swollen
Oncocyte or extract are aided with immunostimulant immune patients, but countless clinical practices proves that this strategy is invalid：From
The tumor cell vaccine of body, which is immunized, to stimulate out effective immune response in patient's body, so as to limit the growth of tumour and hair
Exhibition.Although the approved a such vaccine Provenge of FDA, for treating prostate cancer, clinical effectiveness is extremely limited, it is contemplated that
It can shortly be eliminated.Therefore, it is considered that tumor vaccine is not the outlet for the treatment of of cancer.
Since dendritic cells discovery and its key function in immunological defence illustrate and find be loaded with allosome
Autologous fibroblasts after antigen have antigenicity (Madhav V.Dhodapka r et al., J.Clin.Invest.104:
173-180 (1999), the various vaccines based on dendritic cells are just designed and developed, and the content of experiment includes various cells
Condition of culture, the source of antigen and the approach and the compatibility of adjuvant that load strategy and be immunized.But by effort for many years,
Before up to date, clinical effectiveness all shows that these vaccines can not stimulate out sufficiently strong response with patient
(Gabriela Andrea Pizzurro and María Marcela Barrio Frontiers in Imuunology,
March 2015,Volume 6,Article 91)。
Fusion cell vaccine made of merging the dendritic cells and tumour cell of patient was once sent to hope, because fusion is thin
The protein component of tumour cell part in born of the same parents can continue to synthesize in fused cell, and be fused dendritic cells ingredient in cell
It is processed.In theory, all neoantigen peptides of tumour cell are likely to by the surface of submission to fused cell.Use this
The Fusion cell vaccine of sample goes immune autologous patient, is expected to stimulate out strong immune response, limits the growth of tumour.Sorry
It is that although extremely successful in this tactful system in vitro, and sufficiently strong immune response cannot be stimulated out in vivo, thus
Be defeated (Gong J, et al. .Nat Med 3 (5) in clinic:558-561,1997,Koido S,Gong
J.Anticancer Res 33(2):347-354,2013)。
Not long ago, the researcher of Stanford University reported new DC vaccinations.In vitro, they are by heterologous antibody
It keeps the temperature to form complex altogether with tumour cell, then be kept the temperature altogether by complex and with the homologous DC of tumour.Author has found, such to obtain
To DC vaccines can it is homologous individual in induce strong immune response, the same tumor being newly inoculated with can not only be inhibited thin
The growth of born of the same parents, moreover it is possible to inhibit development (Yaron Carmi the et al., Nature, 2015May of already existing same tumor
7；521(7550):99–104).Subsequent research furthers elucidate, in order to effectively inhibit and the tumour in contact element, it is necessary to whole
Body activating immune system (Spitzer MH et al., Cell, 2017Jan 26；168(3):487-502.).But it is any with
The problem of DC vaccines are the strategy of means, and all there are operational difficulties, time-consuming, somewhat expensive.
Recently, the research team of the U.S. and Germany reports the achievement that tumour is resisted using tumor neogenetic Antigenic Peptide respectively.
They are the complete sequence analysis of the complete sequence analysis or expressing gene group by the genome to tumor tissues, and positioning is all
Catastrophe point, then analyzed using MHC binding peptides forecasting software, determine the range of neoantigen peptide.Team of Harvard directly synthesizes
Antigenic Peptide, then Antigenic Peptide is immunized together together with immunostimulant homologous patient (Ott PA et al.,
Nature.2017Jul 13；547(7662):217-221.)；The team of Germany is then the RNA of composite coding Antigenic Peptide, and will
It is embedded in liposome, and liposome then is fed back to homologous patient, activates DC cells (the Kranz LM et in blood plasma
al.,Nature.2016Jun 16；534(7607):396-401.).In terms of limited clinical data, both of which obtains
Ideal therapeutic effect.
The characteristics of one of the above research is common is to embody one-to-one therapeutic thoughts, that is, attempts to use individual tumors
Whole abrupt informations of tissue stimulate or prepare DC cells, so as to the immune system for exciting homologous individual internal, to internal
Homologous tumour implements attack.Such strategy represents the direction for the treatment of of cancer, and still, the cost of operation is huge, nothing
By be that the time is upper or money on.
Invention content
For above-mentioned problem of the prior art, the new approaches that are prepared the present invention provides a kind of tumor vaccine and new
Method, one aspect of the present invention provide a kind of tumor cell vaccine, and concrete scheme is as follows：
A kind of tumor cell vaccine, the tumor cell vaccine is to pass through compound-modified tumour cell as chief active
Ingredient, the compound can recognize that molecule for antigen presenting cell；The tumour cell is the homologous tumour cell of inactivation, that is,
From the tumour cell of sufferers themselves.
Preferably, the antigen presenting cell can recognize that molecule directly modifies the surface of the tumour cell.
Preferably, the antigen presenting cell can recognize that molecule modifies tumor cell surface indirectly by intermediate compound.
Preferably, the antigen presenting cell can recognize that molecule is alloantibody, and the alloantibody is exogenous anti-
Body.The alloantibody derives from the foreign serum or antibody preparation or thin through tumour without being stimulated by Immunel response
Born of the same parents or the foreign serum or antibody preparation of tumour cell extract immunostimulation.
Preferably, the antigen presenting cell can recognize that molecule is pattern recognition receptors on antigen presenting cell
The molecule that (pattern-recognition receptors) is identified, including naturally occurring and artificial synthesized.
Preferably, the antigen presenting cell can recognize that molecule is pathogen surface associated molecule.It is it is furthermore preferred that described anti-
Former presenting cell can recognize that molecule is mannatide.
Preferably, it is described by sole active agent of the compound-modified tumour cell for the tumor vaccine.It is described
The other compositions of tumor vaccine are auxiliary material, without activity.
Second aspect of the present invention provides the method for preparing above-mentioned tumor vaccine, includes the following steps：
S1：Inactivation treatment is carried out after homologous tumour cell is extracted, then can recognize that molecule is repaiied with antigen presenting cell
The tumour cell after modification is obtained after adoring its surface；
S2：Using human vaccine's preparation conventional method by the tumour cell after modification obtained in S1 be prepared into it is any can
Medicinal vaccine injecta.
Preferably, before step S1, step S0 is further included：It is carried out after homologous tumour cell is extracted large-scale thin
Born of the same parents cultivate to obtain a large amount of homologous tumour cell.
Preferably, inactivation treatment is irradiation inactivated in the S1.
It is furthermore preferred that the irradiation inactivated is Co 60 inactivation, the dose irradiation 10~20 that inactivation condition is 10~20Grays
Minute.
Antigen presenting cell in the S1 can recognize that molecule can directly modify tumor cell surface or pass through centre
Compound modifies tumor cell surface indirectly.Modification reaction can include the chemical combination of one or several kinds of antigen presenting cell identifications
Object；The chemical nature of modification reaction can be covalently attached or non-covalent affine combination or two ways are used in combination.
Third aspect present invention also discloses a kind of application of above-mentioned tumor cell vaccine in tumor is prepared.
Compared with prior art, the invention has the advantages that：
The present invention can recognize that molecule modifies tumour cell in vitro using antigen presenting cell in a creative way, so after modification
Tumor cell vaccine can be identified by antigen presenting cell in vivo, and then be swallowed.Tumour cell content (packet after endocytosis
Include tumor associated antigen molecule and neoantigen peptide) processed by antigen presenting cell after performance or submission in cell surface, then
Corresponding immune effector cell is activated, starts the W-response of immune system, reach limitation tumor development and treats the mesh of tumour
's.Tumor vaccine disclosed in the present invention is prepared simply, at low cost, and short preparation period, is that provides the art a kind of new
Effective tumor vaccine.
Specific embodiment
With reference to specific embodiment, the present invention is further explained.It should be understood that these embodiments are only used for helping to illustrate this
It invents rather than limits the scope of the invention.
The preparation of 1 tumor vaccine of embodiment
1.1 experiment material
Sp2/0 cells, derived from U.S. ATCC；Mannatide-be purchased from (middle inspection institute of Shanghai Yuan Ye bio tech ltd
Product)；EDC is purchased from Shanghai Yuan Ye bio tech ltd (Acros products)；MES solution (0.1mol/L, pH5.0), purchase
In Shanghai Yuan Ye bio tech ltd.
1.2 experimental procedure
Sp2/0 cells are directly modified using mannatide in the present embodiment, concrete operations are as follows：
By 107A sp2/0 cells, 1 milligram of mannatide, 1 milligram of EDC addition, 1 milliliter of MES buffer solution (0.1mol/L,
PH5.0 in), the mixing on shaking table at room temperature.Reaction obtains the sp2/0 cells after modification after 2 hours, then killed cells,
Any pharmaceutical vaccine injecta is prepared into using vaccine preparation conventional method and obtains tumor vaccine.
The preparation of 2 tumor vaccine of embodiment
1.1 experiment material
Sp2/0 cells, derived from U.S. ATCC；Mannatide-be purchased from (middle inspection institute of Shanghai Yuan Ye bio tech ltd
Product)；EDC is purchased from Shanghai Yuan Ye bio tech ltd (Acros products)；MES solution (0.1mol/L), is purchased from Shanghai
Yuan Ye bio tech ltd；Streptavidin (SA), is purchased from Beijing Suo Laibao Science and Technology Ltd；Biotinylation reagent, purchase
In Pierce companies of the U.S..
1.2 experimental procedure
Sp2/0 cells are modified using mannatide indirectly in the present embodiment, concrete operations are as follows：
(1) biotinylation sp2/0 cells
By 107A sp2/0 cells and 10-200 micrograms biotinylation reagent are added in 1 milliliter of PBS (pH7.6), in room temperature
Under do not stop mixing, after reaction 2 hours, cell, centrifugal condition 800-1500rpm, 5min is collected by centrifugation.Then it is washed repeatedly with PBS
It washs 2 times, removes remaining biotinylation reagent in cell, then cell is resuspended in PBS in PBS, obtains biotinylation
Sp2/0 cells.
(2) streptavidin and mannatide are connected with EDC methods
By 0.1 milligram of streptavidin, 1 milligram of mannatide, 0.1 milligram of EDC adds in 1 milliliter of MES buffer solution
In (0.1mol/L, pH5.0), do not stop mixing on shaking table at room temperature.Reaction obtains streptavidin/mannatide after 2 hours
Couplings.
(3) tumor vaccine is produced
In 1 milliliter of PBS, by 107The biotinylation obtained in the ratio mixing step (1) of cell and 0.1-1 milligrams of SA
Sp2/0 cells and step (2) in the obtained streptavidin be combineding with each other and mannatide, be placed at room temperature for 20 minutes, no
When mixing.After reaction, cell (800-1500rpm, 5min) is collected by centrifugation.Then it is washed repeatedly with PBS 2 times, removal is thin
Then cell is resuspended to obtain the sp2/0 cells (10 after modification by remaining reactant in born of the same parents with PBS7Cells/ml).
3 tumor vaccine of embodiment is used for immunization experiment
1.1 experimental animal
BALB/C mice is purchased from Chinese Academy of Sciences's Shanghai Experimental Animal Center.Sp2/0 tumour cells are derived from BALB/C mice,
So with homology.Tumour can be led to by being inoculated into BALB/C mice.
1.2 immune response
10 mouse are divided to two groups, experimental group and control group, every group 5.Experimental group receives sp2/0 cell vaccines (~106Carefully
Born of the same parents), control group receives PBS.It is immune to be total to twice, it is spaced 6 days (D1, D7).The hypodermic injection of femoribus internus, 2 points, every 0.25
Milliliter.
1.3 tumor cell inoculation
There is no the sp2/0 cells (10 of modified to all mouse inoculations within 12nd day5Cell/every), abdomen inoculation.Then
Observe tumorigenic situation.
1.4 experimental result
Control group all grows tumour, and dead in one month.And 3 mouse of experimental group do not grow tumour, one month
It is inoculated with sp2/0 oncocytes again afterwards, also not bearing tumor.It is such the result shows that, the tumour cell of modified pierces in Mice Body
Swash and immune resistance, the challenge of same tumor cell can be resisted, and obtain immunological memory, the hair of similar tumour can be prevented
It is raw.
Specific embodiments of the present invention are described in detail above, but it is intended only as example, it is of the invention and unlimited
It is formed on particular embodiments described above.To those skilled in the art, it is any to the equivalent modifications that carry out of the present invention and
It substitutes also all among scope of the invention.Therefore, the impartial conversion made without departing from the spirit and scope of the invention and
Modification, all should be contained within the scope of the invention.
Claims (10)
1. a kind of tumor cell vaccine, which is characterized in that using the compound-modified tumour cell of process as main active,
The compound can recognize that molecule for antigen presenting cell；The tumour cell is the homologous tumour cell of inactivation.
2. tumor vaccine according to claim 1, which is characterized in that the antigen presenting cell can recognize that molecule is directly repaiied
Adorn the surface of the tumour cell.
3. tumor vaccine according to claim 1, which is characterized in that the antigen presenting cell can recognize that molecule in
Between compound modify tumor cell surface indirectly.
4. tumor vaccine according to claim 1, which is characterized in that the antigen presenting cell can recognize that molecule is allosome
Antibody.
5. tumor vaccine according to claim 1, which is characterized in that the antigen presenting cell can recognize that molecule is antigen
The molecule that pattern recognition receptors are identified on presenting cell, including naturally occurring and artificial synthesized.
6. tumor vaccine according to claim 1, which is characterized in that described by compound-modified tumour cell is institute
State the sole active agent of tumor vaccine.
A kind of 7. method for preparing the tumor vaccine in claim 1-6 described in any one, which is characterized in that including following step
Suddenly：
S1：Will homologous tumour cell extract after carry out inactivation treatment, then with antigen presenting cell can recognize that molecular modification its
The tumour cell after modification is obtained behind surface；
S2：The tumour cell after modification obtained in S1 is prepared into using human vaccine's preparation conventional method any pharmaceutically acceptable
Vaccine injecta.
8. the method according to the description of claim 7 is characterized in that before step S1, step S0 is further included：Homologous is swollen
Large-scale cell culture is carried out after oncocyte extraction and obtains a large amount of homologous tumour cell.
9. the method according to the description of claim 7 is characterized in that inactivation treatment is irradiation inactivated in the S1.
10. application of the tumor cell vaccine in tumor is prepared according to any one in claim 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810067095.7A CN108175853A (en) | 2018-01-24 | 2018-01-24 | A kind of tumor cell vaccine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810067095.7A CN108175853A (en) | 2018-01-24 | 2018-01-24 | A kind of tumor cell vaccine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108175853A true CN108175853A (en) | 2018-06-19 |
Family
ID=62551313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810067095.7A Pending CN108175853A (en) | 2018-01-24 | 2018-01-24 | A kind of tumor cell vaccine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108175853A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109294998A (en) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | A kind of RFF1 cell |
| CN115998851A (en) * | 2022-12-28 | 2023-04-25 | 四川康德赛医疗科技有限公司 | Individuation mRNA composition, vector, mRNA vaccine and application thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057235A2 (en) * | 2006-10-25 | 2008-05-15 | Newlink Genetics | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| WO2009117116A2 (en) * | 2008-03-20 | 2009-09-24 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
| CN102166356A (en) * | 2011-04-12 | 2011-08-31 | 西安交通大学 | Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same |
| CN102552892A (en) * | 2011-12-27 | 2012-07-11 | 郑骏年 | Mannan-modified hTRT (human Telomerase Reverse Transcriptase) gene-carrying and adeno-associated virus (AAV)-inducing targeting dendritic cell (DC) vaccine and preparation method thereof |
| US20130149331A1 (en) * | 2011-05-03 | 2013-06-13 | Peng George Wang | Rhamnose and forssman conjugated immunogenic agents |
| CN103230600A (en) * | 2013-04-08 | 2013-08-07 | 四川大学 | HBx-modified liver-cancer-inhibiting whole-cell vaccine, and preparation method and application thereof |
| CN103705915A (en) * | 2013-12-30 | 2014-04-09 | 山东大学 | Rhamnose modified tumor whole-cell vaccine |
| CN103800896A (en) * | 2012-11-15 | 2014-05-21 | 厦门鹭佳生物科技有限公司 | Preparation method and application of autologous tumor vaccine |
| CN104258381A (en) * | 2014-09-26 | 2015-01-07 | 广州复大医疗股份有限公司复大肿瘤医院 | Ovarian cancer stem cell vaccine as well as preparation method and application thereof |
| CN106668851A (en) * | 2016-12-12 | 2017-05-17 | 成都育芽科技有限公司 | Preparation method of lung cancer stem cell vaccine for obviously improving immunocompetence |
| WO2017147600A1 (en) * | 2016-02-25 | 2017-08-31 | Briacell Therapeutics Corp. | Whole-cell cancer vaccines and methods for selection thereof |
-
2018
- 2018-01-24 CN CN201810067095.7A patent/CN108175853A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008057235A2 (en) * | 2006-10-25 | 2008-05-15 | Newlink Genetics | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| WO2009117116A2 (en) * | 2008-03-20 | 2009-09-24 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
| CN102166356A (en) * | 2011-04-12 | 2011-08-31 | 西安交通大学 | Application of alpha-mannatide as vaccine adjuvant and vaccine preparation prepared using same |
| US20130149331A1 (en) * | 2011-05-03 | 2013-06-13 | Peng George Wang | Rhamnose and forssman conjugated immunogenic agents |
| CN102552892A (en) * | 2011-12-27 | 2012-07-11 | 郑骏年 | Mannan-modified hTRT (human Telomerase Reverse Transcriptase) gene-carrying and adeno-associated virus (AAV)-inducing targeting dendritic cell (DC) vaccine and preparation method thereof |
| CN103800896A (en) * | 2012-11-15 | 2014-05-21 | 厦门鹭佳生物科技有限公司 | Preparation method and application of autologous tumor vaccine |
| CN103230600A (en) * | 2013-04-08 | 2013-08-07 | 四川大学 | HBx-modified liver-cancer-inhibiting whole-cell vaccine, and preparation method and application thereof |
| CN103705915A (en) * | 2013-12-30 | 2014-04-09 | 山东大学 | Rhamnose modified tumor whole-cell vaccine |
| CN104258381A (en) * | 2014-09-26 | 2015-01-07 | 广州复大医疗股份有限公司复大肿瘤医院 | Ovarian cancer stem cell vaccine as well as preparation method and application thereof |
| WO2017147600A1 (en) * | 2016-02-25 | 2017-08-31 | Briacell Therapeutics Corp. | Whole-cell cancer vaccines and methods for selection thereof |
| CN106668851A (en) * | 2016-12-12 | 2017-05-17 | 成都育芽科技有限公司 | Preparation method of lung cancer stem cell vaccine for obviously improving immunocompetence |
Non-Patent Citations (6)
| Title |
|---|
| BERD D: "M-Vax: an autologous, hapten-modified vaccine for human cancer", 《EXPERT OPINION ON BIOLOGICAL THERAPY》 * |
| WANG W, LI Y, WANG Y等: "Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
| ZHANG X, SHI X, LI J等: "A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer", 《THE JOURNAL OF UROLOGY》 * |
| 张信基: "一种新型治疗膀胱转移癌疫苗-SA-GM-CSF膜修饰MB49膀胱癌细胞", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
| 陈殿君，李晓松，赵辉等: "半抗原DNP 修饰自体肿瘤疫苗治疗晚期恶性黑色素瘤的临床研究", 《中国癌症防治杂志》 * |
| 黄文俊，曾晓荣: "肿瘤细胞疫苗的研究进展", 《泸州医学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109294998A (en) * | 2018-09-30 | 2019-02-01 | 北京鼎成肽源生物技术有限公司 | A kind of RFF1 cell |
| CN115998851A (en) * | 2022-12-28 | 2023-04-25 | 四川康德赛医疗科技有限公司 | Individuation mRNA composition, vector, mRNA vaccine and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bruun et al. | Engineering a rugged nanoscaffold to enhance plug-and-display vaccination | |
| CN107522772B (en) | Short peptide, application of short peptide as vaccine adjuvant and vaccine using short peptide as vaccine adjuvant | |
| CN104147597A (en) | Yeast-based vaccines as immunotherapy | |
| CN107488235B (en) | A kind of preparation and application of new enhanced antigen joint polypeptid induction liver cancer-specific CTL cell | |
| CN109865134A (en) | A kind of preparation method and applications of hybridization nanometer tumor vaccine | |
| US6656481B1 (en) | Vaccinal preparations | |
| CN108175853A (en) | A kind of tumor cell vaccine and preparation method thereof | |
| CN103906760B (en) | Human lactoferrin derived peptide for use as an antigen masking agent | |
| Vane et al. | Genetic engineering and pharmaceuticals | |
| WO2017177907A1 (en) | Anti-immune checkpoint pd-l1 and pd-l2 tumor vaccines | |
| CN112516297A (en) | Preparation method and application of antigen and adjuvant co-delivery nano vaccine based on protamine as carrier | |
| WO2023109704A1 (en) | Antibody synthetic bacterium-nano stimulator hybrid and anti-tumor application thereof | |
| CN101163716A (en) | Interleukin-6 polyethylene glycol conjugate and its preparing method and use | |
| EP2112160B1 (en) | Immunotherapeutic formulations to generate autoantibodies capable to avoid the binding of interleukin-2 to its receptor. Their use in the treatment of cancer | |
| Jin et al. | Administration of soft matter lipid-DNA nanoparticle as the immunostimulant via multiple routes of injection in vivo | |
| JP2003506314A (en) | Use of the enteric bacterial protein OMPA in combination with an antigen to elicit an antiviral, antiparasitic or antitumor cytotoxic response | |
| CN107286245A (en) | PD-L1 and PD-L2 recombinant proteins and application thereof | |
| CN111423504A (en) | Melanoma-specific antigenic peptide, peptide complex, and artificial antigen-presenting cell | |
| CN102838679B (en) | The preparation and application of Her2 neu antigen positive tumor therapeutic vaccines | |
| US20040001847A1 (en) | Method and composition to elicit an effective autologous antitumoral immune response in a patient | |
| CN113813375A (en) | Composition of novel anti-new coronavirus compound and application of composition in medicine for preventing and treating coronavirus infection diseases | |
| CN107249628A (en) | For the immunogenicity of the shared DNA vaccination of synthesis of the optimization of Porcine epidemic diarrhea virus | |
| JP2021523127A (en) | Artificial indiscriminate T helper cell epitope that promotes target antibody production with limited T cell inflammatory response | |
| CN109675018A (en) | A kind of drug and its application for coating skin surface | |
| CN114790248B (en) | MUC1-PDL1-IgG1Fc tumor vaccine and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180619 |
|
| RJ01 | Rejection of invention patent application after publication |